Processing protocol

When sufficiently high levels of expression and protein accumulation are achieved, efficient downstream processing protocols must be developed to insure product quality and the economic feasibility of production. As the demand for safe, recombinant pharmaceutical proteins continues to expand, the market potential of plant-produced recombinant proteins is considerable. Molecular farming can produce recombinant proteins at a lower cost than traditional expression systems based on microbial or animal cell culture, and without the risk of contamination with human pathogens. 

Milk is biochemically well characterized, and the physicochemical properties of the major native milk proteins of various species are well known. This helps rational development of appropriate downstream processing protocols (Table 5.8). 

Contaminant-clearance validation studies are of special signibcance in biopharmaceutical manufacture. As discussed in Section 7.6.4, downstream processing must be capable of removing contaminants such as viruses, DNA and endotoxin from the product steam. Contaminant-clearance validation studies normally entail spiking the raw material (from which the product is to be purihed) with a known level of the chosen contaminant and subjecting the contaminated material to the complete downstream processing protocol. This allows determination of the level of clearance of the contaminant achieved after each purihcation step, and the contaminant reduction factor for the overall process. 

Microreactor and microprocess technology has, in some fine-chemical cases, approached commercial applications and become competitive with existing technology. Two main developments are awaited. Firstly, optimizing the process protocol conditions such that the chemistry is set to the limit of the reactor s capabilities in terms of mass and heat transfer. This so-called novel chemistry approach achieves the highest process intensification and can improve the costing of microprocess... 

Rather than assess all attributes for each prototype, a subset of properties was selected for use as a screening process. Protocols for screening tests that are broadly equivalent to those implemented by the Unilever product scientists during the development of Dove have appeared in the patent literature, and we note these references in Table 9.3-1. The tests were relatively easy to perform, and served to rapidly eliminate unsuitable compositions. Only if a prototype passed all screening tests would it be subject to the remaining property assessments, listed in Table 9.3-2. 

Sterilization process protocol and record (when needed)... 

There are major differences in tissue processing protocols with variations in the time of immersion in formalin and alcohols. These variables can be controlled and standardized for the individual laboratory but in the case of tissue blocks prepared in other laboratories such variations may significantly affect the staining of tissue antigens. 

There are several general issues where ionic liquids differ from aqueous solutions. Some of these are discussed in greater detail in the preceding chapters and all are discussed in more detail in a recent review [67]. The key issues are clearly associated with developing non-aqueous processing protocols and accounting for the differences between the physical properties of a non-viscous polar fluid and a viscous ionic liquid. 

The interface of protein separation to protein detection is in many cases a time-consuming and laborious exercise. We developed in this human study a simple and highly efficient process protocol whereby we could advance the protein samples that had been excised from the 2-D gel and digested. The digests were run through the SMEC preparation and analyzed by MALDI-TOF... 

It is currently unclear whether, based on the current state of the art, a patent following the above-mentioned example could be extended to recombinant derivatives of the native protein. One might argue that, once the native protein is known and accessible, it needs no inventiveness to sequence the amino acids for parts of this protein, synthesize the corresponding DNAs, use these as probes to identify and isolate the entire coding sequence of the protein, which is then inserted into a suitable expression system to produce the protein in any desired form and quantity. Experience, however, teaches that it still requires some non-obvious steps and usually more than a limited degree of experimentation (often even a stroke of luck) to get there and to achieve the desired utility with recombinant polypeptides. For a vaccine it may be necessary to find and express the important epitopes in an appropriate (still unknown) way and to develop adequate purification and further processing protocols (with unpredictable technical... 

There are three main batch process protocols for reaction of silanes with Grignard reagents. Addition of the silane to the Grignard reagent (normal addition) is preferred when full substitution is desired. The reaction is single-pot , in that the Grignard can be formed and then reacted without transfer. An example of a product produced by normal addition is triethylsilane. Addition of the Grignard to the silanes (reverse addition) is preferred... 

Regular meetings are essential for full REB reviews with records of minutes documenting all decisions and dissents with explanations. Decisions must be made impartially. If desired, an investigator may participate in the discussion with an opportunity to reply to comments but cannot be present for the decision process. Protocols may be resubmitted if rejected. If a decision cannot be reached initially an appeal board may be utilized however, appeals following REB decisions are not considered. 

Proprietary signal processing protocols based on FCS and related single molecule-based confocal fluorescence methodologies. 

An interdigital slit-type high-pressure micromixer followed by a tube (0.9 mm inner diameter 2.6 m long) was used [48]. The micromixer-tube reactor was submersed into a thermostat bath for temperature setting. HPLC pumps fed the monomer and initiator flows. A back-pressure cartridge (70 bar) and a pressure sensor served for pressure control. The temperature was set to 105 °C. The processing protocol was carried out conventionally, using the specs of similar batch processes. 

Bead mix 240 J,L of streptavidin coated Sepharose beads, 4560 pL of 2X binding buffer and 3600 pL of 18.2 mQ water per 96-well plate (the magnetic bead processing protocol for a PSQ96 or PSQ96MA is described elsewhere [8]). Excess Sepharose/binding buffer mix can be stored in a glass bottle at 4°C. 96-well plate shaker, e.g., Eppendorf thermomixer (Fisher Scientific, Hampton, NH). 

---